未登录

M

Matthew T. Ballo

University of Tennessee System

H指数:54

被引数:8,838

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma in older adults: A single center institutional study

老年新诊断胶质母细胞瘤的肿瘤治疗电场（TTFields）疗法：一项单中心机构研究

Journal of Geriatric Oncology

IF2.7

2026-08-010

PRE

Tumor-treating fields dosimetry in glioblastoma: Insights into treatment planning, optimization, and dose-response relationships

胶质母细胞瘤的肿瘤治疗领域剂量学: 对治疗计划，优化和剂量反应关系的见解

NEURO-ONCOLOGY ADVANCES

IF4.1

2024-03-020

OAAI

TUMOR TREATING FIELDS (TTFIELDS) REAL-WORLD EXPERIENCE IN NEWLY DIAGNOSED GLIOBLASTOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF OVERALL SURVIVAL

IF13.4

2023-09-080

OA

Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis

肿瘤治疗场 (TTFields) 治疗与新诊断胶质母细胞瘤生存率的关系: 系统回顾和荟萃分析

JOURNAL OF NEURO-ONCOLOGY

IF3.1

2023-07-2626

OAAI

Association of Tumor Treating Fields (TTFields) with survival in newly diagnosed glioblastoma: A systematic review and meta-analysis

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Predicting future cancer incidence by age, race, ethnicity, and sex

JOURNAL OF GERIATRIC ONCOLOGY

IF2.7

2023-01-0126

PRE

Determinants of tumor treating field usage in patients with primary glioblastoma: A single institutional experience

原发性胶质母细胞瘤患者肿瘤治疗领域使用的决定因素: 单一机构经验

NEURO-ONCOLOGY ADVANCES

IF4.1

2022-09-158

OAAI

The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2022-04-0125

PRE

The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials

JOURNAL OF GERIATRIC ONCOLOGY

IF2.7

2022-04-016

OA

The role of radiation therapy in the management of cutaneous malignancies. Part II: When is radiation therapy indicated?

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2021-09-017

PRE

The role of radiation therapy in the management of cutaneous malignancies. Part I: Diagnostic modalities and applications

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2021-09-011

PRE

Randomized phase II study of a home-based walking intervention for radiation-related fatigue among older patients with breast cancer

JOURNAL OF GERIATRIC ONCOLOGY

IF2.7

2021-03-0110

PREAI

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma

FRONTIERS IN ONCOLOGY

IF3.3

2020-07-2845

OAAI

TTFIELDS DOSE DISTRIBUTION AND TUMOR GROWTH PATTERNS CONFIRM CLINICAL ACTIVITY OF TTFIELDS: MRI ANALYSIS OF THE RANDOMIZED PHASE 3 EF-14 TRIAL

IF13.4

2019-09-060

OAAI

Tumor Treating Fields Therapy Influences Patterns of Failure in Glioblastoma Patients in a Dose-Dependent Manner: A Multidisciplinary Analysis of the Randomized Phase III EF-14 Clinical Trial

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2019-09-010

OAAI

Intensity-Modulated Versus Three-Dimensional Conformal Radiotherapy for Cervical Cancer: National Trend and Survival

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2019-09-011

OAAI

Single Institutional Experience with Tumor-Treating Field Compliance and Overall Survival in Patients with Primary Glioblastoma

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2019-09-011

PREAI

Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2019-08-0190

OAAI

Increasing Tumor Treating Fields dose at the tumor bed improves survival: Setting a framework for TTFields dosimetry based on analysis of the EF-14 Phase III trial in newly diagnosed glioblastoma

CANCER RESEARCH

IF16.6

2019-07-011

PRE

Definitive Pelvic Radiotherapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2019-01-188

OAAI